How To Download Statement Of Results
Alterio Wihl
The signatories of this joint statement affirm that the prospective registration and timely public disclosure of results from all clinical trials is of critical scientific and ethical importance. Furthermore timely results disclosure reduces waste in research, increases value and efficiency in use of funds and reduces reporting bias, which should lead to better decision-making in health.
Within 12 months of becoming a signatory of this statement, we each pledge to develop and implement a policy with mandated timeframes for prospective registration and public disclosure of the results of clinical trials that we fund, co-fund, sponsor or support. We each agree to monitor registration and endorse the development of systems to monitor results reporting on an ongoing basis. We agree to share challenges and progress in the monitoring of these policies. We agree that transparency is important and therefore the outputs from the monitoring process will be publicly available.
The benefits of implementing and monitoring policies on public disclosure of results relate to access to more complete information about the results of clinical trials. The benefits are summarised below.
Finally patients seeking enrollment in clinical trials will be able to access results from previously completed clinical trials in their area, as they make decisions on which clinical trials they may wish to seek enrollment into.
There will be modest costs associated with public disclosure of clinical trial results. The costs of disseminating the results of research are a minor component of the overall costs of conducting such research, and results reporting is an essential component of the research enterprise. The resource allocation, public health and scientific benefits - together with the need to meet ethical imperatives - far outweigh the costs.
At the time of the initial grant submission, the plan for public disclosure of results should be included, including specific time bound commitments. Reasonable funds to enable compliance with these considerations is a cost eligible item in clinical trial budgets.
Reporting of previous trials realises the value of funding; therefore the contribution made from reporting previous trials, whatever their results, will be considered in the assessment of a funding proposal. When a PI applies for new funding, they may be asked to provide a list of all previous trials on which they were PI within a specified timeframe and their reporting status, with an explanation where trials have remained unreported.
We are all supporters of open access policies, and consider that publications describing clinical trial results should be open access from the date of publication, wherever possible. Open access fees should be included in clinical trial budget requests, if necessary.
While this statement focuses on clinical trials, transparency and reduction of waste and reporting bias are important for other types of research including public health intervention studies, observational studies, implementation research and pre-clinical studies of experimental therapeutics and preventives.
Dr Soumya Swaminathan, Director-General of the Indian Council of Medical Research
\"We need timely clinical trial results to inform clinical care practices as well as make decisions about allocation of resources for future research. We welcome the agreement of international standards for reporting timeframes that everyone can work towards.\"
Dr John-Arne Røttingen, Chief Executive of the Research Council of Norway
\"We fully support this statement and look forward to working towards increasing the availability of results from clinical trials. The public disclosure of results from clinical trials will improve resource allocation to research in a broad sense, and is also in line with our policies on transparency, and on open access.\"
Dr Micaela Serafini, Medical Director, Médecins Sans Frontières
\"Timely reporting of all clinical trial results is of upmost importance to MSF allowing fully informed decisions when it comes to health strategies, treatments and diagnostics. We fully support this move towards increased transparency and accountability in clinical research.\"
Dr David C. Kaslow, Vice President of Essential Medicines at PATH
\"PATH remains deeply committed to the timely public disclosure of clinical trial results to accelerate development of new interventions and to ensure access to and transparency of safety and efficacy data, no matter if positive or negative. Full and consistent implementation of WHO standards on reporting clinical trial results is an important step towards better understanding the risks and benefits of vaccines, drugs, and medical devices, and the optimal use of new interventions.\"
Dr Soumya Swaminathan, Director-General of the Indian Council of Medical Research
"We need timely clinical trial results to inform clinical care practices as well as make decisions about allocation of resources for future research. We welcome the agreement of international standards for reporting timeframes that everyone can work towards."
Dr John-Arne Røttingen, Chief Executive of the Research Council of Norway
"We fully support this statement and look forward to working towards increasing the availability of results from clinical trials. The public disclosure of results from clinical trials will improve resource allocation to research in a broad sense, and is also in line with our policies on transparency, and on open access."
Dr Micaela Serafini, Medical Director, Médecins Sans Frontières
"Timely reporting of all clinical trial results is of upmost importance to MSF allowing fully informed decisions when it comes to health strategies, treatments and diagnostics. We fully support this move towards increased transparency and accountability in clinical research."
Dr David C. Kaslow, Vice President of Essential Medicines at PATH
"PATH remains deeply committed to the timely public disclosure of clinical trial results to accelerate development of new interventions and to ensure access to and transparency of safety and efficacy data, no matter if positive or negative. Full and consistent implementation of WHO standards on reporting clinical trial results is an important step towards better understanding the risks and benefits of vaccines, drugs, and medical devices, and the optimal use of new interventions."
My IF statement above is in cell Score1, pulling the result from the drop down choice in cell Technology Relevance3. My issue is that the result pulled for each column labeled Score1, Score2, Score3, etc. do not return a numeric value where I can sum them up as a single total.
The CUSTOMER table in my database has three columns: username, pwd, and email. But nonetheless, no results are returned when I assign the $username variable to a value I know exists in the database. I know it exists because this query
760c119bf3